Hyperglycemia Treatment Market Share

Global Hyperglycemia Treatment Market Overview

Hyperglycemia Treatment Market Size was valued at USD 0.65 Billion in 2023. The Global Hyperglycemia Treatment industry is projected to grow from USD 0.72 Billion in 2024 to USD 1.59 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 11.02% during the forecast period (2024 - 2032).

Hyperglycemia is an excess of glucose in the bloodstream, and is often associated with diabetes mellitus. It occurs when the body does not have enough insulin to control the sugar level or unable to produce the insulin. Furthermore, hyperglycemia if remains untreated may cause serious complications such as nerve damage or neuropathy, kidney damage, kidney failure, cardiovascular disease, eye disease, and skin problems such as bacterial and fungal infections. The major signs of hyperglycemia are polydipsia (a great thirst), polyuria (a need to urinate often), and a dry mouth.

Increasing prevalence of diabetes, and growing investment in biotechnology and pharmaceutical industries, and rising need for the better treatment methods drive the growth of the Hyperglycemia Treatment Market.

According to the WHO, the global prevalence of diabetes among adults over 18 years of age has risen from 4.7% in 1980 to 8.5% in 2014. Where as in 2015, 1.6 million deaths were caused due to diabetes. Another, 2.2 million deaths were attributed to high blood glucose level in 2012.

According to the WHO estimates, neurological disorders are responsible for 4.5%-11% of all illnesses including low or high income economies across the globe. This is higher than the number of respiratory ailments, gastrointestinal disorders, or cancers, and the burden is expected to increase further over the coming years.

Moreover, increasing awareness about diabetes care and management, and advancing technology in medical devices are adding fuel to the growth of the market. Furthermore, increasing prevalence of obesity and consumption of unhealthy diet also drive Hyperglycemia Treatment Market growth. 

However, availability of expensive treatment and poor reimbursement policy are some of the factors, which may slow the Hyperglycemia Treatment Market growth during the forecast period.

Segmentations

The hyperglycemia treatment market is segmented on the basis of treatment, mode of administration, and end user.

On the basis of treatment, it is segmented into fluid replacement, electrolyte replacement, insulin therapy, and drugs. The drugs segment is further segmented into sulfonylureas, biguanides, thiazolidinediones, and others.

On the basis of mode of administration, it is segmented into topical, oral, and others.

On the basis of end user, the market is segmented into hospitals & clinics, retail pharmacy, and others

Regional Analysis

The Americas dominates the hyperglycemia treatment market owing to well-developed technology, increasing patient with diabetes, increasing prevalence of neurological disorders, increasing patient population of kidney failure caused by severe hyperglycemia, high healthcare spending, and increasing government support for research & development. Furthermore, increased R&D activities and the concentration of major companies have fuelled the growth of the market in this region.

Europe holds the second position in the hyperglycemia treatment market owing to the government support for research & development and availability of funds for research. This is expected to continue to drive the European market over the forecasted period. For instance, countries like Germany and France are increasing investment in the healthcare domain.

Asia Pacific is the fastest growing hyperglycemia treatment market owing to the presence of rapidly developing healthcare technology, huge patient population, and high healthcare expenditure. Moreover, increasing demand for new treatment methods in countries like India and South Korea is likely to emerge as  the fastest growing market across the globe. Furthermore, increasing demand for quality devices in the healthcare projected to lead to the use of advanced equipment, which, in turn, will increase the market growth of the hyperglycemia treatment in the region.

On the other hand, the Middle East & Africa holds the least share of the market due to limited availability of medical facilities, less availability of funds, and poor political conditions in Africa.

Key Players

• Novo Nordisk A/S


• Merck & Company Inc.


• Medtronic


• Johnson & Johnson Services, Inc.


• Teva Pharmaceuticals Ltd.


• Eli Lilly and Company


• Sanofi S.A.


• Home Diagnostics


• Bayer AG


• Bristol-Myers Squibb


• Abbott